Comparing SG&A Expenses: Merck & Co., Inc. vs Amicus Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals, the strategic allocation of Selling, General, and Administrative (SG&A) expenses can be a game-changer. Over the past decade, Merck & Co., Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting trends in their SG&A spending.

Merck & Co., Inc.: A Steady Giant

From 2014 to 2023, Merck's SG&A expenses have shown a relatively stable pattern, averaging around $10 billion annually. Despite a slight dip in 2020, Merck's spending rebounded, reflecting its robust market position and strategic investments.

Amicus Therapeutics, Inc.: A Growth Story

Conversely, Amicus Therapeutics has seen a dramatic increase in SG&A expenses, growing by over 1,200% from 2014 to 2023. This surge underscores Amicus's aggressive expansion and commitment to innovation.

Insights and Implications

These trends highlight the diverse strategies of pharmaceutical giants and emerging players, offering insights into their market dynamics and future trajectories.